The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells

被引:19
作者
Bi, Ling [1 ]
Xie, Chanlu [2 ,3 ,4 ,5 ]
Yao, Mu [3 ,4 ,5 ]
Hnit, Su Su Thae [2 ]
Vignarajan, Soma [3 ,4 ]
Wang, Yilun [3 ,4 ,5 ]
Wang, Qian [6 ,7 ]
Xi, Zhichao [8 ,9 ]
Xu, Hongxi [8 ,9 ]
Li, Zhong [10 ]
de Souza, Paul [11 ]
Tee, Andrew [12 ,13 ]
Wong, Matthew [12 ,13 ]
Liu, Tao [12 ,13 ]
Zhao, Xiaodong [14 ]
Zhou, Jia [1 ]
Xu, Ling [1 ]
Dong, Qihan [2 ,3 ,4 ,5 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Oncol, Shanghai, Peoples R China
[2] Western Sydney Univ, Sch Sci & Hlth, Sydney, NSW, Australia
[3] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia
[4] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
[5] Royal Prince Alfred Hosp, Dept Endocrinol, Sydney, NSW, Australia
[6] Centenary Inst, Origins Canc Lab, Camperdown, NSW, Australia
[7] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[8] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China
[9] Engn Res Ctr Shanghai Coll TCM New Drug Discovery, Shanghai, Peoples R China
[10] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China
[11] Western Sydney Univ, Sch Med, Sydney, NSW, Australia
[12] Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia
[13] UNSW Med, Ctr Childhood Canc Res, Sydney, NSW, Australia
[14] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biol, Shanghai, Peoples R China
基金
英国医学研究理事会;
关键词
SPT16; SSRP1; G(0); SKP2; MYC; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; QUIESCENCE DECISION; UBIQUITIN LIGASE; CYCLE REENTRY; EXPRESSION; P27(KIP1); PIRH2; MECHANISMS; SUBUNITS;
D O I
10.1002/ijc.32065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer cell repopulation through cell cycle re-entry by quiescent (G(0)) cell is thought to be an important mechanism behind treatment failure and cancer recurrence. Facilitates Chromatin Transcription (FACT) is involved in DNA repair, replication and transcription by eviction of histones or loosening their contact with DNA. While FACT expression is known to be high in a range of cancers, the biological significance of the aberrant increase is not clear. We found that in prostate and lung cancer cells FACT mRNA and protein levels were low at G(0) compared to the proliferating state but replenished upon cell cycle re-entry. Silencing of FACT with Dox-inducible shRNA hindered cell cycle re-entry by G(0) cancer cells, which could be rescued by ectopic expression of FACT. An increase in SKP2, c-MYC and PIRH2 and a decrease in p27 protein levels seen upon cell cycle re-entry were prevented or diminished when FACT was silenced. Further, using mVenus-p27K(-) infected cancer cells to measure p27 degradation capacity, we confirm that inhibition of FACT at release from quiescence suppressed the p27 degradation capacity resulting in an increased mVenus-p27K(-) signal. In conclusion, FACT plays an important role in promoting the transition from G(0) to the proliferative state and can be a potential therapeutic target to prevent prostate and lung cancer from progression and recurrence.
引用
收藏
页码:164 / 178
页数:15
相关论文
共 51 条
  • [1] Models, mechanisms and clinical evidence for cancer dormancy
    Aguirre-Ghiso, Julio A.
    [J]. NATURE REVIEWS CANCER, 2007, 7 (11) : 834 - 846
  • [2] Attwood K, 2017, BREAST CANCER-TARGET, V9, P301, DOI 10.2147/BCTT.S126390
  • [3] Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide- responsive and - resistant glioblastoma
    Barone, Tara A.
    Burkhart, Catherine A.
    Safina, Alfiya
    Haderski, Gary
    Gurova, Katerina V.
    Purmal, Andrei A.
    Gudkov, Andrei V.
    Plunkett, Robert J.
    [J]. NEURO-ONCOLOGY, 2017, 19 (02) : 186 - 196
  • [4] A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy
    Becker, Walter
    [J]. FEBS JOURNAL, 2018, 285 (07) : 1203 - 1211
  • [5] Berges RR, 1995, CLIN CANCER RES, V1, P473
  • [6] SKP2 Oncogene Is a Direct MYC Target Gene and MYC Down-regulates p27KIP1 through SKP2 in Human Leukemia Cells
    Bretones, Gabriel
    Acosta, Juan C.
    Caraballo, Juan M.
    Ferrandiz, Nuria
    Teresa Gomez-Casares, M.
    Albajar, Marta
    Blanco, Rosa
    Ruiz, Paula
    Hung, Wen-Chun
    Pilar Albero, M.
    Perez-Roger, Ignacio
    Leon, Javier
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (11) : 9815 - 9825
  • [7] Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
    Carter, Daniel R.
    Murray, Jayne
    Cheung, Belamy B.
    Gamble, Laura
    Koach, Jessica
    Tsang, Joanna
    Sutton, Selina
    Kalla, Heyam
    Syed, Sarah
    Gifford, Andrew J.
    Issaeva, Natalia
    Biktasova, Asel
    Atmadibrata, Bernard
    Sun, Yuting
    Sokolowski, Nicolas
    Ling, Dora
    Kim, Patrick Y.
    Webber, Hannah
    Clark, Ashleigh
    Ruhle, Michelle
    Liu, Bing
    Oberthuer, Andre
    Fischer, Matthias
    Byrne, Jennifer
    Saletta, Federica
    Thwe, Le Myo
    Purmal, Andrei
    Haderski, Gary
    Burkhart, Catherine
    Speleman, Frank
    De Preter, Katleen
    Beckers, Anneleen
    Ziegler, David S.
    Liu, Tao
    Gurova, Katerina V.
    Gudkov, Andrei V.
    Norris, Murray D.
    Haber, Michelle
    Marshall, Glenn M.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (312)
  • [8] Molecular regulation of stem cell quiescence
    Cheung, Tom H.
    Rando, Thomas A.
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2013, 14 (06) : 329 - 340
  • [9] The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
    Chu, Isabel M.
    Hengst, Ludger
    Slingerland, Joyce M.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (04) : 253 - 267
  • [10] SSRP1 Contributes to the Malignancy of Hepatocellular Carcinoma and Is Negatively Regulated by miR-497
    Ding, Qianshan
    He, Ke
    Luo, Tao
    Deng, Yunchao
    Wang, Hanning
    Liu, Hao
    Zhang, Jinqian
    Chen, Kaiyun
    Xiao, Jinfeng
    Duan, Xiaopeng
    Huang, Rui
    Xia, Zhenglin
    Zhou, Wenjie
    He, Jinliang
    Yu, Honggang
    Jiao, Xingyuan
    Xiang, Guoan
    [J]. MOLECULAR THERAPY, 2016, 24 (05) : 903 - 914